NCT06115681Completed
Real-world Study of Dedifferentiated Liposarcoma Patients in China
Demographic, Clinical Characteristics, and Treatment Outcomes Associated With Dedifferentiated Liposarcoma Patients in China
Source: ClinicalTrials.gov · Last updated 10 Jul 2025
Brief summary (registry, in English)
This study will characterize patients with dedifferentiated liposarcoma (DDLPS) in China, including an understanding of demographic, and clinical characteristics as well as treatment patterns and clinical outcomes associated with the current real-world treatment.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1390 (actual)
- First submitted
- 27 Oct 2023
- Start date
- 13 Mar 2024
- Primary completion date
- 15 May 2024
- Lead sponsor
- Boehringer Ingelheim
- Diseases
- Sarcoma
- NCT number
- NCT06115681
What you commit to
- Study type: Observational
- Participants enrolled: 1390
- From 13 Mar 2024 to the primary completion date, 15 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Patient has two or more documented clinical visits in the National Anti-Tumor Drug Surveillance System (NATDSS) network on or after January 1, 2013.
- Patient has a confirmed diagnosis of dedifferentiated liposarcoma (DDLPS) during his/her lifetime.
- At least 18 years old at the date of initial diagnosis.
- No exclusion criteria are applied.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Jishuitan Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.